Longwood Capital Partners »

An2 Therapeutics shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2023-09-30 $214k 13k 16.08

More positions owned by Longwood Capital Partners

Replimune Group Call Option (REPL)
Sarepta Therapeutics Call Option (SRPT)
Taysha Gene Therapies Com Shs (TSHA)
Apellis Pharmaceuticals (APLS)
Aadi Bioscience (AADI)
Praxis Precision Medicines I
Rayzebio
Rocket Pharmaceuticals (RCKT)
Ventyx Biosciences (VTYX)
Disc Medicine (IRON)
Kura Oncology (KURA)
Cymabay Therapeutics
Vaxcyte (PCVX)
Immunovant (IMVT)
Syndax Pharmaceuticals (SNDX)

View all positions for Longwood Capital Partners

Top funds holding An2 Therapeutics

RA Capital Management
BVF
Citadel Advisors
Frazier Life Sciences Management
Henderson Group
Avidity Partners Management
Vanguard Group
Octagon Capital Advisors
Marshall Wace
Nantahala Capital Management
T. Rowe Price Associates
Citigroup
Jane Street
Victory Capital Management
Alyeska Investment Group

View all funds holding An2 Therapeutics